Highlights d Mutant HTT overexpression causes impairment of autophagy, resulting in AGO2 accumulation d Activation of autophagy reverses AGO2 accumulation in neurons d AGO2 accumulation results in a global increase in miRNA levels d AGO2 re-localizes to stress granules, resulting in loss of miRNA activity SUMMARY Many neurodegenerative diseases are characterized by the presence of intracellular protein aggregates, resulting in alterations in autophagy. However, the consequences of impaired autophagy for neuronal function remain poorly understood. In this study, we used cell culture and mouse models of huntingtin protein aggregation as well as post-mortem material from patients with Huntington's disease to demonstrate that Argonaute-2 (AGO2) accumulates in the presence of neuronal protein aggregates and that this is due to impaired autophagy. Accumulation of AGO2, a key factor of the RNA-induced silencing complex that executes microRNA functions, results in global alterations of microRNA levels and activity. Together, these results demonstrate that impaired autophagy found in neurodegenerative diseases not only influences protein aggregation but also directly contributes to global alterations of intracellular post-transcriptional networks.
INTRODUCTION
MicroRNAs (miRNAs) are small non-coding RNAs that provide post-transcriptional control of gene expression. miRNAs play an important role in the brain, where hundreds of different miRNAs are expressed and thought to regulate thousands of transcripts (Petri et al., 2014) . Several lines of evidence indicate that miRNAs are likely to play an important role in neurodegenerative diseases (NDDs) (Maciotta et al., 2013) . For example, con-ditional deletion of Dicer, a key enzyme in the miRNA biogenesis pathway, results in neuronal cell death (Pang et al., 2014) . In addition, there are numerous reports describing changes in miRNA expression levels in NDDs such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) (Maciotta et al., 2013) . It is therefore likely that alterations in miRNA levels participate in the pathophysiological events underlying cell dysfunction and loss in these diseases.
AD, PD, HD, ALS, and other diseases form a large class of NDDs known as proteinopathies, characterized by the formation of specific protein aggregates in the brain. Neurons appear to be particularly sensitive to aggregation-prone proteins, indicating that neuronal survival is highly dependent on maintaining efficient protein quality control with rapid removal of toxic and aggregated proteins (Cortes and La Spada, 2014) . However, it remains unclear how protein aggregation influences intracellular functions and why specific neuronal subtypes ultimately are lost in these different disorders. For example, it is well established that neuronal gene expression programs are severely altered in these disorders, but mechanistic insight into how neuronal protein aggregation results in selective disturbances in transcriptional networks is currently lacking.
Macroautophagy (hereafter referred to as autophagy) is an evolutionary conserved lysosomal degradation pathway characterized by the formation of an autophagosome, a doublemembraned vesicle that isolates the cytoplasmic cargo for destruction (Martin et al., 2015) . The autophagosome ultimately fuses with a lysosome, forming the autolysosome where the cargo is degraded. Several studies have documented altered autophagy in NDDs, and boosting autophagy has been proposed as a novel therapeutic strategy (Martin et al., 2015) . In addition to clearing toxic and misfolded proteins, we and others have recently found that autophagy also plays a critical role in maintaining brain homeostasis through selective protein degradation (Petri et al., 2017; Yamamoto and Yue, 2014) . One possibility is therefore that alterations of autophagy in NDDs also directly influence other intracellular neuronal functions.
One protein that is of interest in this regard is Argonaute-2 (AGO2), which is degraded by selective autophagy under basal conditions (Gibbings et al., 2012) . AGO2 is a core component of the RNA-induced silencing complex (RISC), which executes miRNA functions. In the RISC, AGO2 has multiple roles, including biogenesis and maturation of miRNAs, as well as direct binding of mature miRNAs (Petri et al., 2014) . AGO2 also provides endoribonuclease activity that enables direct degradation of miRNA target transcripts, as well as recruitment of other downstream factors that mediate transcriptional repression or decay (Bossé and Simard, 2010) . Several studies have shown that intracellular AGO2 protein is carefully titrated at a post-transcriptional level and that miRNA-free AGO2 is degraded through a specific mechanism (F€ ullgrabe et al., 2014) . Removal of mature miRNAs by deleting the miRNA biogenesis factors Dgcr8 or Dicer results in a parallel reduction of AGO2 protein levels (Gibbings et al., 2012; Savas et al., 2008) . Furthermore, overexpression of AGO2 is very difficult to achieve, further suggesting a feedback regulation of AGO2 protein levels (F€ ullgrabe et al., 2014; He et al., 2012) . Together, these observations indicate that the regulation of intracellular AGO2 protein levels is critical in maintaining appropriate miRNA activity.
In this study, we used both cell culture and mouse models as well as post-mortem material from patients with HD to demonstrate that AGO2 accumulates as a result of impaired autophagy in neurons expressing aggregating mutant Huntingtin (mHTT). This AGO2 accumulation results in a global alteration of miRNA activity. Our results provide mechanistic insights into how impairment in autophagy in NDDs contributes to dysregulation of miRNA networks.
RESULTS

mHTT-Mediated Impairment of Autophagy Correlates with Accumulation of AGO2
To investigate a potential link between alterations in autophagy in NDDs and AGO2 expression levels, we transduced 293T cells with lentiviral vectors expressing exon 1 of wild-type HTT (wtHTT, 18 polyQ repeats) or mutant HTT (mHTT 66Q, 66 polyQ repeats) ( Figure 1A) . HTT is mutated in HD, where a polyglutamine expansion in the first exon ultimately leads to a toxic gain of function for mHTT and protein aggregation (DiFiglia et al., 1997) . Vector transduction was also combined with chloroquine (CQ) treatment, which prevents both the fusion of the autophagosome with the lysosome and lysosomal protein degradation, or with wortmannin (W) treatment, a phosphatidylinositol 3-kinase (PI3K) inhibitor that provides an early block of autophagy and inhibits microtubule-associated protein 1A/1Blight chain 3 (LC3) lipidation. Using this system, we monitored autophagic activity by assessing the levels of LC3II, LC3-II/ I ratio, p62, and LAMP1 using western blot (WB) and immunocytochemistry (ICC) and found, in line with other studies (Martin et al., 2015) , that expression of mHTT mediates a late-step block of autophagy characterized by failure of fusion of the autophagosome and the lysosome (Figures S1A-S1R).
We next investigated AGO2 expression levels using WB in 293T cells transduced with mHTT. We found a significant increase in the AGO2 protein level compared to wtHTT-expressing cells, whereas there was no difference in the AGO2 mRNA level ( Figures 1B, 1C , and S1S). A similar increase in AGO2 protein was also seen in wtHTT-transduced cells when we inhibited autophagy using CQ or W ( Figures 1B, 1C , and S1S), whereas we found no additive effect of mHTT expression after CQ or W treatment. Together, these data demonstrate that mHTT-mediated autophagy impairment results in accumulation of AGO2 at a post-transcriptional stage in mHTT-expressing cells in a manner similar to that seen following chemical autophagy inhibition. (I) AGO2 protein accumulates after 3 weeks in AAV-mHTT-injected animals. AGO2 protein is marked with an asterisk. n = 8 (4 animals/ group). (J) AGO2 mRNA levels were not changed 3 weeks after mHTT overexpression. n = 3. (K) Relative AGO2 mRNA levels were not changed 3 weeks after mHTT overexpression. n = 5. (L-N) AGO2 protein accumulates in AAV-mHTT (M), but not in AAV-wtHTT (L)-injected animals 8 weeks after injection. (N) There were significantly more, as well as bigger puncta in the AAV-mHTT-injected mice than in those injected with AAV-wtHTT. n = 27 (3 animals/ group).
(O-R) WB autophagic protein expression levels in AAV-mHTT and wtHTT-injected animals (O). Increased expression levels of the autophagic markers p62 (P) and LC3-II (Q) and LC3-II/LC3-I ratio (R) are detected 3 weeks after AAV-mHTT injections. n = 8 (4 animals/ group). (S) Accumulation of LAMP1 was seen after 3 weeks in AAV-mHTT-injected but not in AAV-wtHTT-injected mice. LAMP1 is marked with an asterisk. n = 10 and 20 for wtHTT and mHTT, respectively (4 animals/ group).
(T-V) IHC demonstrate p62 accumulation in the AAV-mHTT (U) compared to AAV-wtHTT (T)-injected animals. (V) Relative p62 dot number and size were significantly increased in mHTT-overexpressing animals compared to wtHTT 8 weeks after injection. n = 19 and 24 for AAV-wtHTT-and AAV-mHTT-injected animals, respectively (3 animals/ group). WB values were normalized to LV-wtHTT non-treated (B) or AAV-wtHTT (I and O-S) expression levels and corrected to actin values. ***p < 0.001, **p < 0.01, *p < 0.05; nonparametric Kruskal-Wallis test was used for (B); two-tailed two-sample unequal variance t tests were used for all other cases. All data are shown as mean ± SEM. Scale bars represent 50 mm (E-G), 10 mm (L and M), and 10 mm (T and U). See also Figures S1-S3 and S6 and Tables S1 and S3.
AGO2 Accumulates in Striatal Neurons Expressing mHTT
The most affected neuronal cell type in HD is medium spiny neurons in the striatum. To study the role of mHTT in modulating autophagy and AGO2 levels in striatal neurons in vivo, we generated adeno-associated viral (AAV) vectors expressing either exon 1 wtHTT or mHTT under the control of the neuron-specific synapsin promoter that were subsequently injected into the striatum of the mouse brain ( Figure 1D ). Mice injected with AAV-mHTT showed a progressive increase in intracellular mHTT inclusions, whereas AAV-wtHTT did not develop such inclusions ( Figures 1E-1H ). We also found progressive loss of DARPP-32 levels in AAV-mHTT-injected mice in the absence of neuronal cell loss, indicating progressive dysfunction of striatal medium spiny neurons ( Figures S2A-S2E ).
We next investigated AGO2 levels after AAV-mHTT injections using WB and found an almost 3-fold increase 3 weeks post-injection ( Figure 1I ). We did not observe any changes in AGO2 mRNA levels, as monitored by RNA sequencing (RNA-seq) or by qRT-PCR ( Figures 1J and 1K ). When we investigated AGO2 expression in the striatum using immunohistochemistry (IHC) with two different antibodies, we found cytoplasmic AGO2 protein accumulation in the animals injected with AAV-mHTT but not in animals injected with AAV-wtHTT ( Figures 1L-1N and S3A-S3D). We did not see any colocalization between AGO2 and mHTT aggregates in animals injected with AAV-mHTT, suggesting that AGO2 accumulation is not a result of direct binding to HTT aggregates ( Figures 1L-1N ). We also investigated the level of other AGO proteins in the presence of mHTT but did not find any changes in the protein or mRNA level for AGO1 and AGO4 ( Figures S3E-S3G ). Together, these data show that expression of mHTT in striatal neurons results in protein aggregation that is associated with formation and accumulation of AGO2 protein puncta.
Activation of Autophagy Reverses AGO2 Accumulation in Striatal Neurons Expressing mHTT
We next investigated alterations in autophagy following AAV-mHTT injections in the mouse brain. Using WB and IHC analysis of dissected striatal tissue from mice injected with AAV-mHTT and AAV-wtHTT, we found increased levels of p62 and LC3-II as well as an increased LC3-II/I ratio, suggesting impaired autophagosome-lysosome fusion or inhibition of lysosome-mediated proteolysis ( Figures 1O-1R , S3H, and S3I). We also found an increase in the lysosomal marker LAMP1 (Figures 1S, S3J , and S3K). We found no changes in the mRNA levels of any of these markers, as monitored by RNA-seq ( Figures S3L-S3N ). Confocal analysis of HTT/p62 co-staining revealed numerous p62-positive mHTT aggregates in AAV-mHTT animals ( Figures 1T-1V ). p62positive clusters were found to accumulate adjacent to the protein aggregates, with significant p62 sequestration within aggregates ( Figure S3O ). Although accumulated p62 and AGO2 puncta were often found in the same cells, we never saw colocalization of these two proteins, which is in line with previous data showing that AGO2 is degraded by autophagy in a p62-independent manner (Figures S3P-S3S; Table S1 ; Gibbings et al., 2012; Savas et al., 2008) . In addition, AGO2 puncta never colocalized with the autophagosomal marker LC3 in mHTT-expressing cells, whereas we found several examples of colocalization between AGO2 and LC3 in wtHTT-expressing neurons, indicating that AGO2 is selectively degraded by autophagy in neurons expressing the wt protein but not in neurons expressing the mutant protein ( Figures S3T and S3U ). Together, these results demonstrate that expression of mHTT leads to a distinct impairment in autophagy that correlates with the accumulation of AGO2.
To provide a mechanistic link between the decrease in autophagy activity and AGO2 accumulation, we next overexpressed Beclin-1 (BECN1), a positive regulator of autophagosome formation, together with mHTT in the mouse brain (Figures S4A and S4B) . Three weeks after co-delivery of AAV-mHTT and AAV-BECN1, the number of p62 aggregates was dramatically lower compared to animals injected with AAV-mHTT alone ( Figures  2A-2C ). We also measured the changes in the level of LC3 with WB and IHC to see whether there was increased autophagy activity and found a significant increase in the level of LC3-II and LC3-II/I ratio ( Figure S4C ). LC3-positive dots accumulated in the co-injected animals around the mHTT aggregates ( Figures  S4D and S4E ). We did not detect any changes in the level of LAMP1 using IHC or WB, indicating that BECN1 overexpression did not affect the formation and amount of lysosomes or endosomes ( Figures S4F-S4I ). We also found that BECN1 accumulated around mHTT inclusions, which is in line with its association with newly formed autophagosomes ( Figures S4J-S4L ).
Strikingly, AGO2 dot number and size were significantly reduced in BECN1 co-expressing mice ( Figures 2D-2F ). Thus, BECN1 co-overexpression decreased the number of p62 aggregates and reduced AGO2 dot size and number, providing a mechanistic link between autophagy and AGO2 accumulation.
It is worth noting that the number of HTT inclusions was 3 times less in co-injected mice than in animals injected with AAV-mHTT only ( Figures 2G-2I ) and that the DARPP-32 levels in striatal projection neurons were significantly higher ( Figure 2J ), suggesting that autophagy activation using AAV-BECN1 interferes with the progression of the mHTT-associated disease phenotype.
AGO2 Accumulation in a HD Mouse Model and Postmortem HD Tissue
Although the AAV-mHTT model is a good tool to study protein aggregation in neurons, it fails to recapitulate many of the features of HD (e.g., pathology in non-neuronal cells). To investigate a potential dysregulation of AGO2 in a more disease-relevant model of HD, we used BACHD mice, which express full-length mHTT with 97 glutamine repeats under the control of endogenous HTT regulatory sequences (Gray et al., 2008) . At 6 months of age, which represents an early manifest stage, we found an accumulation of p62 inclusions in striatal neurons of BACHD mice that was not seen in striatal tissue from wt littermates ( Figures 3A-3D ). We also detected AGO2 accumulation in striatal tissue of BACHD mice but not in controls ( Figures 3A-3C and 3E). These AGO2 puncta were primarily found in the cytoplasm of cells with a neuronal morphology. As with the AAV-model, we never saw colocalization of p62 and AGO2 protein, although p62 aggregates and AGO2 puncta were often found in the same cells ( Figure 3F ; Table S1 ).
We then performed IHC on post-mortem striatal material from HD patients of different pathological grades and healthy age-matched individuals (Table S2 ). We found AGO2 accumulation in cells in striatal tissue of the HD patients but not in healthy individuals ( Figure 3G -3M). We also found accumulation of p62 adjacent to mHTT inclusions in the neurons that were not seen in the striatal tissue of healthy individuals (Figures S5A and S5B) . Similarly, we did not see colocalization of p62 and AGO2 protein ( Figure 3N ; Table S1 ). These data demonstrate that AGO2 accumulates in a HD mouse model as well as in HD patients.
AGO2 Accumulation Results in a Global Increase in miRNA Levels AGO2 levels are directly related to the number of mature miRNAs present within a cell (Diederichs and Haber, 2007) . This suggests that the increase in AGO2 levels that occurs following mHTT expression may result in an increased level of mature miRNAs, which may be coupled to profound effects on the activity of miRNAs. To investigate alterations in miRNA levels, we performed small RNA-seq on striatal brain tissue dissected 3 weeks after AAV-wtHTT and AAV-mHTT injections. This time point was chosen because there were no major cell death or phenotypic changes in the surrounding glia and only minor electrophysiological alterations in striatal neurons, representing an early time point in the disease course (Figures S2F-S2Q and S5C; Table S3 ). When investigating global miRNA levels, we found a more than 50% global increase in mature miRNA levels in AAV-mHTT-injected mice compared to AAV-wtHTT-injected mice ( Figures 4A and 4B ). We found that most individual miRNAs were overexpressed, including abundant neuronal miRNAs such as miR-128, miR-9, and let-7 (D-F) TIA1 accumulated in AAV-mHTT (E)-injected animals compared to AAV-wtHTT (D). (F) Overexpression of mHTT significantly increased TIA1 size. n = 11 for AAV-wtHTT and n = 9 for AAV-mHTT (3 animals/group). (G) TIA1 protein level was significantly higher in AAV-mHTT-injected animals compared to AAV-wtHTT. n = 10 or 8 (5 animals in the AAV-wtHTT group and 4 animals in the AAV-mHTT-injected group). (H) TIA1 showed increased colocalization with AGO2. n = 11 for AAV-wtHTT and n = 9 for AAV-mHTT (3 animals/group).
(legend continued on next page) (Figures 4C, S5D, and S5E) . These data demonstrate that the increase in AGO2 levels correlates with an increased level of mature miRNAs.
AGO2 Puncta Localize to Stress Granules, Resulting in Loss of miRNA Activity The subcellular localization of AGO2 is known to be important for the activity of miRNA-mediated gene silencing (Leung and Sharp, 2013) . This suggests that alterations of AGO2 levels as well as accumulation of AGO2 in puncta in mHTT-expressing neurons may affect the activity of miRNAs. AGO2 protein is normally diffusely distributed throughout the cytoplasm but has also been found in processing bodies (P-bodies) and stress granules (SGs) (Anderson and Kedersha, 2006; Leung and Sharp, 2013) . The shuffling of AGO2 through different cytoplasmic compartments is directly related to the activity of miRNAs. For example, AGO2 found in SGs contains miRNAs but does not participate in gene silencing (Leung and Sharp, 2013) .
In mice injected with AAV-mHTT, we found a 4-fold increase in the size of SGs, as monitored with the cytotoxic granule-associated RNA binding protein TIA1 ( Figures 4D-4F ). We also found an increase in total TIA1 levels, as measured with WB ( Figure 4G ). Remarkably, we found a clear increase in the amount of AGO2 localizing to SGs in mHTT-expressing cells (Figures 4D, 4E , and 4H; Table S1 ). On the contrary, we did not find a significant increase in colocalization of AGO2 puncta to P-bodies (Figures 4I-4K; Table S1 ). We also found that overexpression of AAV-BECN1, together with AAV-mHTT, significantly reduced TIA1 colocalization with AGO2 ( Figures S5F-S5H ; Table S1 ). These data demonstrate that a substantial fraction of AGO2 re-localizes to SGs in mHTT-expressing neurons. Because AGO2-miRNA complexes lose their silencing activity in SGs, this indicates that an overall loss of miRNA activity should occur following mHTT expression.
To test this hypothesis, we investigated neuronal miRNA activity by performing RNA-seq on striatal tissue injected with either AAV-mHTT or AAV-wtHTT and quantified the expression of all detectable mRNAs. We then selected targets of three of the most highly expressed neuronal miRNAs in the mouse striatum, miR-128, let-7, and miR-9, based on computationally predicted and evolutionary conserved miRNA target sites (TargetScanMouse 7.1) ( Figure 4L ; Table S4 ; . We assessed the global fold change distribution of targets in cumulative fraction graphs (y axis) and found that the expression levels of these miRNA targets, but not non-neuronal miRNA targets or non-targeted mRNAs, were significantly increased in AAV-mHTT-injected animals, indicating a de-repression of targets of the most abundant neuronal miRNAs (Figures 4M and S5I) . Interestingly, genes targeted by all three miRNAs showed an even stronger shift toward de-repression ( Figure 4M ). Together, these results are in line with other studies where relocalization of AGO2 to SGs is associated with a loss of miRNA activity (Leung and Sharp, 2013; Qi et al., 2008; Wu et al., 2011) .
To investigate the potential function of the de-repressed miRNA targets, we performed gene ontology analysis on the set of genes targeted by the three most abundant miRNAs (let-7, miR-128, and miR-9) and found these to be highly enriched for terms such as neurological system processes, axon guidance, and synaptic functions ( Figures 4N and S5J ). These are all mechanisms that are disrupted in HD and other NDDs.
In an independent analysis, we also confirmed that experimentally identified neuronal miR-128 targets were upregulated upon mHTT expression ( Figure S5K ; . It is worth noting that the phenotype of miR-128 KO mice is characterized by neuronal hyperactivity, a phenomenon that is also found in models of HD, directly linking our analysis to HD-like phenotypes .
DISCUSSION
Several hundred miRNAs are expressed in the brain and are thought to regulate thousands of transcripts (Petri et al., 2014) . Therefore, any alteration in the miRNA network is likely to have a significant effect on neuronal function. In line with this, there is extensive literature documenting that conditional deletion of Dicer or individual miRNAs such as miR-128 in postmitotic neurons (including striatal neurons) results in phenotypes that are reminiscent of HD (Cheng et al., 2014; Schaefer et al., 2007; . Thus, an alteration in miRNA activity in HD and other NDDs is likely to contribute to the early intracellular pathology, including alterations in neuronal activity and synaptic plasticity.
The current work provides mechanistic insight into how protein aggregation causes global alterations of miRNA level and activity through a direct link between impaired autophagy and AGO2 accumulation because of mHTT expression. Our results are in line with previous studies demonstrating that selective autophagy is required to maintain appropriate AGO2 levels and that AGO2 levels need to be carefully regulated to sustain appropriate levels of mature miRNAs (F€ ullgrabe et al., 2014; Gibbings et al., 2012; He et al., 2012; Savas et al., 2008) . However, a previous study (I-K) There was no difference in the level of AGO2 co-staining with DCP1A between AAV-wtHTT (I) and mHTT (J)-injected animals. (K) Overexpression of mHTT did not change DCP1A and AGO2 colocalization. n = 6 (3 animals/group). (L) Venn diagram showing the number of unique and shared target genes of let-7, miR-9, and miR-128, as predicted by TargetScan. Only genes with more than 16 reads on average were included and used in the downstream miRNA target analysis. n = 3 (1 animal/ RNA sample). (M) Cumulative fractions of log 2 (mHTT/wtHTT) fold changes of expressed genes (>16 reads) and the predicted targets of let-7, miR-9, and miR-128 as well as the 38 shared targets show a significant upregulation in AAV-mHTT compared to AAV-wtHTT-injected animals. n = 3 (1 animal/sample). *p < 0.05, ***p < 0.001; Wilcoxon rank-sum test with continuity correction was applied to target genes versus all genes). (N) The top 12 most enriched Panther gene ontologies among the set of significantly upregulated (log 2 fold-change > 0.1; *p < 0.05, n = 183) let-7, miR-9, and miR-128 target genes. Fold enrichment: observed number of genes/expected from background population of all expressed genes (>16 reads). Black triangles: p value, binomial distribution test. Numbers by bars indicate the number of observed genes for the given term. All fold changes are shown as log 2 (mHTT/wtHTT). WB values were normalized to AAV-wtHTT-injected expression levels and corrected to actin values. ***p < 0.001; **p < 0.01; *p < 0.05; two-tailed two-sample unequal variance t tests. All data are shown as mean ± SEM. Scale bars represent 5 mm (D and E) and 7.5 mm (I and J). See also Figure S5 and Tables S1, S2, S4, S5, and S6. performed in cancer cell lines found that AGO2 accumulation because of impaired autophagy results in a loss of mature miRNAs. In this study, the authors speculated that this phenomenon was due to an imbalance in the stoichiometry of the RISC complex components (Gibbings et al., 2012) . When we analyzed 293T cells expressing mHTT, we found similar results, including global loss of mature miRNAs ( Figures S5L and S5M ). However, mature neurons do not divide, and, thus, any impairments in autophagy are likely to have different consequences than in dividing cells, which can renew their cytoplasmic content upon cell division.
We found that accumulation of AGO2 in neurons expressing mHTT is linked to accumulation of mature miRNAs. However, mHTT expression also causes a shift in AGO2 localization to SGs, resulting in global loss of miRNA activity despite the increase in mature miRNAs. It thus appears that the consequence of AGO2 accumulation is fundamentally different between neurons and dividing cells, which could be due to the inability of neurons to renew their protein composition during cell division or through the appearance of SGs in mHTT-expressing neurons.
In this study, we used an AAV-based in vivo mouse model. This model has several advantages for studying the transcriptional response to mHTT because it allows for an appropriate control (AAV-wtHTT) and results in neuron-specific expression of mHTT, limiting the effect on surrounding glial cells that otherwise may complicate the analysis. Compared to most transgenic mouse models of NDDs, it also avoids potential developmental or compensatory effects that might arise because of transgene expression in the entire organism during brain development. Our data show that alterations in AGO2 levels following mHTT expression occur at an early time point during the disease course. AGO2 and mature miRNAs are already accumulating 3 weeks following AAV-mHTT injection, a time point when only minor alterations in neuronal functions can be detected, as monitored by DARPP-32 levels or electrophysiological recordings. This suggests that loss of miRNA activity may be an important component of early disease phenotypes in HD. In this respect, our data are in line with a previous study that found a global accumulation of miRNAs at an early stage in a mouse model of HD, and there are also data indicating that mHTT expression impairs miRNA silencing in cell lines (Lee et al., 2011; Savas et al., 2008) . In contrast, our results are inconsistent with several reports of either selective up-or downregulation of individual miRNAs or reports of a global loss of miRNAs in more severe HD mouse models or when analyzing post-mortem tissue (Kocerha et al., 2014; Maciotta et al., 2013) . This discrepancy may, to some extent, be explained by differences in methodology as well as some limitations when using various mouse models and post-mortem material. Alternatively, it may also result from the fact that impairments of the miRNA machinery change as the disease progresses. When we analyzed striatal tissue 6 months after AAV-mHTT injection, when there was clear evidence of striatal and ventricle volume changes that was coupled with atrophy and gliosis, thus reflecting a later-stage time point, we rather find a decrease in AGO2 protein level, as measured by WB, and only detected sparse neurons displaying AGO2 accumulation ( Figures S6A-S6Y ). Similar, we found lower AGO2 levels from HD post-mortem striatal tissue when analyzing global protein levels using WB ( Figure S6Z ). These data raise the possibility that AGO2 accumulation accom-panied by a loss of miRNA activity is a specific feature of earlystage impairment in neurons expressing protein aggregates and impaired autophagy.
In summary, our results suggest that changes in miRNA levels are an early feature of HD that lies downstream of alterations in autophagy. Our data provide a mechanistic link between protein aggregation and post-transcriptional gene regulation, two seemingly unrelated phenomena. Our data also provide further support for developing autophagy-activating therapeutic approaches for HD and other NDDs because they suggest that activation of autophagy will not only clear toxic protein aggregates but also directly restore dysfunctional post-transcriptional gene regulation.
EXPERIMENTAL PROCEDURES
Detailed experimental procedures can be found in the Supplemental Experimental Procedures.
Viral Vectors
To overexpress wtHTT and mHTT, we used previously described third-generation self-inactivating lentiviral vectors encoding the first 171 amino acids of the human huntingtin gene with 18 or 66 CAG repeats under the control of a mouse phosphoglycerate kinase 1 promoter (PGK) (de Almeida et al., 2002) .
Animal Surgery
All animal-related procedures were approved and conducted in accordance with the Committee for Use of Laboratory Animals at Lund University. All mice were adult C57BL/6 females 9 to 10 weeks old at the time of surgery. All stereotactic injections into the striatum were performed as described before with minor changes (Petri et al., 2017) . Injections were unilateral on the right side of the brain with a total of 1 ml of injected virus. The injection coordinates were as follows: anterior/posterior (AP): +0.9 mm; medial/lateral (ML): +/À1.8 mm; dorsal/ventral (DV) (from the dura): À2.7 mm.
Human Tissue
Post-mortem human brain tissue was obtained from the Cambridge Brain Bank (Cambridge, UK) and used under local ethics approval (REC 01/177).
Small RNA-Seq cDNA libraries of small RNA-seq samples were prepared using the New England Biolabs Small RNA Library Prep Kit for small RNA-seq at the Clinical Microarray Core (University of California, Los Angeles [UCLA], CA, USA). Illumina high-throughput sequencing was applied to the samples (total number of reads: in vivo, 228,894,902; in vitro, 71,800,132) .
RNA-Seq
cDNA libraries of the in vitro mRNA samples were prepared using the KAPA Stranded mRNA-Seq Kit from KAPAbiosystems at the Clinical Microarray Core (UCLA, CA, USA). In vivo cDNA libraries were prepared using the Illumina Strand-Specific TruSeq RNA Library Kit using poly(A) selection and sent for sequencing to SciLifeLab. Illumina high-throughput sequencing was applied to all the samples (total read number: in vitro, 180,491,336; in vivo, 356,983,073) .
Statistical Analysis
Two-tailed, two-sample unequal variance t tests were used to analyze means in most cases. One-way ANOVA or nonparametric Kruskal-Wallis test was used in Figures 1B, S1B -S1D, S1M, and S1N with Figures S1Q and S1S depending on normal distribution defined by D'Agostino-Pearson omnibus normality test. The criterion for significance for all analyses was p < 0.05. All data are shown as mean ± SEM.
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(E) AGO1 WB does not show any difference after 3 weeks of AAV-wtHTT or AAV-mHTT injection. AGO1 protein is marked with an asterisk. n = 10 (5 animals/ group).
(F) Relative AGO4 mRNA levels were not changed 3 weeks after AAV-mHTT overexpression with qPCR. n = 10 (5 animals/ group).
(G) RNA-seq experiments showed that AGO1 and AGO4 mRNA levels were not changed 3 weeks after AAV-mHTT overexpression. n = 3 (1 animal/ RNA sample). (B) BECN1 protein level was significantly higher in the AAV-BECN1 co-injected animals compared to AAV-mHTT injected animals. n = 4 (4 animals/ group).
(C) LC3-II protein level was significantly higher coupled with an increased LC3-II/LC3-I ratio in the AAV-BECN1 co-injected animals compared to AAV-mHTT injected animals. n = 8 (4 animals/ group).
(D-E) LC3 dots accumulate inside and around the HTT aggregates 3 weeks after AAV-mHTT+BECN1 co-injection (E) but not in the AAV-mHTT animals (D).
(F-H) LAMP1 dots did not accumulate inside and around the HTT aggregates 3 weeks after AAV-mHTT+BECN1 co-injection (G) or AAV-mHTT injection (F). There was no difference in the relative LAMP1 dot number and size between the two groups (H). n = 26
(3 animals/ group).
(I) LAMP1 protein level did not change after AAV-BECN1 co-injection compared to AAV-mHTT injected animals. n = 8 (4 animals/ group). p53 signaling pathway (04115) axon guidence (04360) regulation of lipolysis in adipocytes (04923) MAPK signaling pathway (04010) miRNAs in cancer (05206) Ras signaling pathway (04014) PI3K-Akt signaling pathway ( (E) qRT-PCR experiments showed significantly more neuronal miR-9 and miR-125 but not glial miR-21 relative miRNA expression level. n = 10 (5 animals/ group).
(F-H) TIA1 showed significantly decreased colocalization with AGO2 (H) in the coinjected animals (G) compared to the AAV-mHTT injected animals (F). n = 9 for AAV-mHTT, and AAV-mHTT+Becn1 (3 animals/ group). *p<0.05; two-tailed two-sample unequal variance t-tests. (C-E) Densitometrical analysis revealed a significant loss of DARPP-32 protein (E) after 6 months of AAV-mHTT injection (D) compared to AAV-wtHTT animals (C). n = 12 (4 animals/ group).
(F-H) Striatal area measurements showed a significant decrease and ventricle area measurements showed a significant increase (H) between the AAV-wtHTT (F) and AAV-mHTT (G) injected animals after 6 months. n = 12 (4 animals/ group).
(I) Densitometrical analysis revealed a significant loss of DARPP-32 protein after 6 months of AAV-mHTT injection. n = 4 (4 animals/ group). (P-R) p62 and HTT accumulated and aggregated in the mHTT (Q and R) overexpressing animals compared to controls (P) at 6 months after injection.
(S-U) AGO2 did not accumulated in the mHTT overexpressing animals (T and U) compared to controls (S) at 6 months after injection.
(V) Relative p62 dot number and size was significantly increased in the mHTT overexpressing animals compared to controls at 6 months after injection. n = 24 (3 animals/ group).
(W) AGO2 accumulated but there was no significant difference in number in the mHTT overexpressing animals compared to controls at 6 months after injection. n = 24 (3 animals/ group).
(X) Densitometrical analysis revealed a significant increase of p62 protein after 6 months of AAV-mHTT injection. n = 4 (4 animals/ group). Number of  CAG repeats  Ctrl1  C572  59  --Ctrl2  PT89  66  --HD1  HD725  58  4  48  HD2  HD715  57  3  47  HD3  HD721  61  2  46 wtHTT and mHTT-injected animals. Related to Figure 1 and S2 .
Whole-cell patch clamp recordings of medium-spiny neurons at 3 weeks after injection. 3 AAV-mHTT and 3 wtHTT injected animals included. There were no major differences in intrinsic membrane properties (i.e. resting membrane potential, cell capacitance, membrane resistance) or the frequency (Hz) of miniature Excitatory Postsynaptic Currents (mEPSC) between the groups. There was a small difference between the amplitude (pA) in mESPC however. The number of patched neurons (n) included in the analysis is written after the statistics in each case.
N of action potentials (AP) represents the maximal number of spikes induced with currents in IV curve, (max 450 pA injected current). All data are shown as mean ± SEM. *p<0.05; twotailed two-sample unequal variance t-tests. 
Viral vectors
Lentiviral vectors were produced in 293T cells as previously described (Zufferey et al., 1997) and titrated by flow cytometry analysis and quantitative PCR analysis as previously described (Georgievska et al., 2004) . The titers of the vectors used in this study were 2.83E+8 for wtHTT and 1.92E+9 TU/mL for mHTT. A MOI of 5 was used for transduction, vector stock was added to the medium, and 24 h later the vector containing media was replaced and changed to fresh culture media.
AAV vectors of serotype 5 encoding wtHTT, mHTT and mouse Beclin-1 were designed and produced as described before . The titer of the injected AAV-wtHTT, mHTT and BECN1 were 1.2E+15, 1.5E+15 and 6.15E+14 genome copies / ml, respectively. The final working dilution in PBS for each vector was 33 %.
Cell culture
All cell culture work on 293T cells was performed as described before (Musiwaro et al., 2013) . Cells were grown in 24 well plates to ≈ 70 % confluence (for immunofluorescence) or ≈ 80 % confluence (for western blotting) in six well plates before any treatments were added. Mammalian phosphatidylinositol 3-kinase was blocked by the addition of 100 nM wortmannin (stock solution: 200 μM in DMSO, stored at −20 °C, Sigma-Aldrich) for 4 hours in the cell medium. Autophagosome maturation and lysosomal fusion was blocked using chloroquine (Sigma-Aldrich) at final concentrations of 100 μM (always fresh solution made in Milli-Q water) in normal cell medium also for 4 h (Musiwaro et al., 2013) .
Electrophysiology
Patch-clamp electrophysiology was performed in mice that had been injected with AAV- 
Immunocytochemistry and high-content screening
For high-content screening (HCS) all cells (treated or not treated) were fixed in 24 well plates with 4 % PFA for 15 minutes, followed by two washing steps with PBS. Staining was performed as previously described (Sachdeva et al., 2010; Thompson et al., 2005) .
Primary anti-mouse p62 (Abcam Cat# ab56416 RRID:AB_945626) antibody was diluted at 1:500. Cy-2 secondary antibody was used in 1:200 (Jackson ImmunoResearch Labs Cat# 715-545-150 RRID:AB_2340846). All fluorescent labelings were counterstained with DAPI. Average p62 dot number and size / well was measured with a Thermo Scientific Cellomics ArrayScan VTI HCS Reader. The cells nuclei were defined by DAPI (Sigma-Aldrich, 1:1,000), the cytoplasm was measured as a ring around the nuclei and p62 dots were detected (with Spot Detection) and measured in each case.
Western Blot
For western blots on 293T cells, the medium was removed from the 6-well plates and the differentially treated cells were lysed in RIPA buffer (Sigma-Aldrich) supplemented with Protease inhibitor cocktail (PIC, Complete, 1:25) for 2 -3 minutes. The cells were scraped off the well and transferred to tubes for incubation on ice for 30 minutes. Afterwards cells were centrifuged at 10,000 x g for 10 minutes at 4 °C. The supernatants were collected and transferred to a new tube and stored at -20 °C.
For western blots from fresh striatal tissue, injected mice were sacrificed by cervical by densitometry using the ImageJ software.
Quantitative real-time PCR
To measure the expression level of different miRNAs and RNAs animals were first injected with AAV-wtHTT or mHTT and sacrificed 3 weeks after injection. Striatal tissue was quickly dissected after cervical dislocation and homogenized in an eppendorf tube in QIAzol Lysis Reagent with a magnetic bead (Qiagen) using a TissueLyser (30 Hz, 2 x 2 minutes). miRNA and total RNA was extracted according to the supplier's recommendations using the mini miRNeasy kit (Qiagen).
cDNA was generated from five AAV-wtHTT and five AAV-mHTT injected animals using To synthesize cDNA from miRNA we used the Universal cDNA synthesis kit (Exiqon).
miRCURY LNA TM PCR primer sets, SNORD65, SNORD-68, hsa-miR-9, hsa-miR-125 and hsa-miR-21 were purchased from Exiqon. SYBR green qRT-PCR was performed.
Relative enrichment of genes was calculated using SNORD65 and SNORD68 as controls.
In all cases data were quantified using the ∆∆Ct method.
Colocalization analysis
All pictures for colocalization analysis were taken with confocal microscope using the same magnification and settings in 2-3 sections from 3-3 animals per group. Pictures were transferred to ImageJ and colors were splitted first. JACoP: Just Another Colocalization Plugin was used for image analysis (https://imagej.nih.gov/ij/plugins/track/jacop2.html) (Bolte and Cordelières, 2006) . In order to determine colocalization between AGO2 -p62, AGO2 -DCP1A or AGO2 -TIA1 two independent methods were used for imaging data analysis. First Pearson's coefficient was determined. Second, Li's intensity correlation analysis was performed to gain further insight into the degree of colocalization. This method calculates the difference from the mean channel intensity for each color at each pixel. Li's intensity correlation analysis was also used to define Li's intensity correlation quotient (ICQ). Colocalization parameters were summarized in Table S1 with % colocalization defined by Pearson's coefficient x 100 or Li's ICQ x 2 x 100. All data are
shown as mean ± SEM.
Analysis of in vivo mouse small RNA-seq data
The 50 bp single end reads were mapped to the mouse genome (mm10) using STAR_2.4.0j (Dobin et al., 2013) . Reads mapping to miRNAs were quantified with FeatureCounts (Liao et al., 2014) using annotation files from miRbase (www.miRbase.org (Kozomara and Griffiths-Jones, 2014)), counting only primary reads. For differential expression analyses (Bioconducter/R package DESeq2) and the identification of miRNA families, data was normalized to the total read number mapping to the genome. MiRNA families were identified based on miRbase annotations (www.miRbase.org (Kozomara and Griffiths-Jones, 2014)).
To investigate relative miRNA levels, reads mapping to miRNAs in mHTT and wtHTT injected animals were normalised to the total number of reads mapping to tRNAs. tRNA annotations were obtained from UCSC Repeat Masker Track (Kersey et al., 2016) . wtHTT miRNA levels were used as reference.
The small RNA-seq data from this publication has been submitted to the NCBI Gene Expression Omnibus database and assigned the GEO series accession number GSE78928.
Analysis of in vitro small RNA-seq data in 293T cells
Previously harvested transduced 293T cells (miRNAEasy kit, Quiagen) were sent for small To investigate relative miRNA levels, reads mapping to miRNAs in mHTT and wtHTT samples were normalised to the total number of reads mapping to repeats obtained from UCSC Repeat Masker Track. wtHTT miRNA levels were used as reference.
The small RNA-seq data from this publication have been submitted to the NCBI Gene Expression Omnibus database and assigned the GEO series accession number GSE78928.
RNA-seq and analysis
Previously harvested transduced 293T cells (miRNAEasy kit, Quiagen) were sent for mRNA-seq to the Clinical Microarray Core (University of California, Los Angeles
[UCLA], CA, USA) (n = 6).
For striatal samples, the striatum was quickly dissected from decapitated vector-injected mice (n = 6), frozen on dry ice and homogenised in Tissue LyserLT (50 Hz, 2 x 2 min).
Total RNA was extracted using the miRNeasy mini kit (Qiagen).
The 50 bp single end reads were mapped to the genome (mm10 for mouse striatal tissue and hg19 for 293T cells). Reads were quantified to Refseq. The normalisation and identification of differentially expressed genes was conducted using the Bioconducter/R package DESeq2.
The RNA-seq data from this publication have been submitted to the NCBI Gene Expression Omnibus database and assigned the GEO series accession number GSE78928.
miRNA target analysis
TargetScan (release 7.1, June 2016), was applied to get predicted targets of let-7, miR-9 and miR-128 . All targets with a cumulative weighted context score < 0 was used in the analysis. We also applied a list of potential miR-128 targets as predicted by AGO2 HITS-CLIP-seq in Camk2a neurons, taking all genes with perfect base pairing of at least 6 nucleotides between miR-128 target sequence and the 3'UTR of AGO2-associated genes . To remove noise from low expressing transcripts, we only included genes with >16 sequencing reads on average through the
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samples. Venn plots were generated using the R package VennDiagram (Hanbo, 2014) .
The R package DESeq2 (Love et al., 2014) was used to calculate fold changes of genes.
Gene ontology enrichment analysis was performed using the online resource of the Gene Ontology Consortium (http://geneontology.org/page/go-enrichment-analysis (Gene Ontology, 2015) , with the Panther classification system (Mi et al., 2016) . Upregulated genes were defined as genes with log2 fold change > 0.1 and p-value < 0.05. This list was tested against a reference background list with all expressed genes (>16 reads) in the samples.
For miRNA target analysis related to Figure S5I we first assessed genes targeted by miRNAs that were not expressed in our samples in Figure S5I . We identified two miRNAs that were completely absent in our AAV-wtHTT or mHTT injected animals, miR-302 and miR-486. However, many target genes of these two miRNAs are redundantly targeted by other miRNAs that are highly expressed in our samples and will therefore be affected by inactivation of those expressed miRNAs. For example: miR-302 alone has 1003 predicted target genes. However, 949 of these genes are targeted by at least one other miRNA that has more than 200 reads. To overcome this issue, we included only miR-302 and miR-486 targets that were not targeted by any other expressed (>200 reads) miRNA. We repeated the same analysis for miR-486 and found that the fold-change distribution of target genes does not show a shift to de-repression as seen with target genes of let-7, miR-9 and miR-128; instead, they are significantly shifted in the opposite direction, suggesting these genes are not affected ( Figure S5I ; pink and green lines).
As an additional control, we analysed all genes that were not targeted by any expressed miRNA. We found 250 miRNAs with >200 reads in the brain samples. We identified 1704 target mRNAs that were not directly targeted by any of these highly expressed miRNAs ( Figure S5I ; orange line of the plot). We have also identified miRNA target genes of non−expressed miRNAs (1021 miRNAs) in neurons where we also removed targets of the highly expressed miRNAs >200 reads, leaving 543 genes not targeted by any highly expressed miRNA in our samples ( Figure S5I ; red line of the plot). These 543 miRNAtargets show no trend of de-repression, such as the target genes of let-7, miR-128 and miR-9. Taken together, in all analyses of target genes of non-expressed miRNAs there is no evidence for target de-repression like the target genes of highly expressed miRNAs (let-7,
miR-128 and miR-9).
Statistical analysis
The intensity of DARPP-32 expression in the striatum was measured on 3 representative sections from each brain using ImageJ. In each case the contralateral, non-injected site was used for normalization.
Amounts of HTT inclusion bodies were quantified by counting the dots in a 1 mm 2 sized area around the needle track in 3 representative sections from each brain.
Striatal and ventricular volumes from animals injected 8 weeks or 6 months previously were measured and calculated with ImageJ. For both wt and mHTT injected animals representative sections were measured from each brain. In all cases the contralateral, noninjected site was used for normalization.
Relative p62, TIA1, LAMP1 and AGO2 dot number and size were defined with ImageJ as previously described (Pircs et al., 2012) . All pictures taken with the confocal microscopy were done using a magnification of 20x or 63x. Pictures of AGO2, TIA1, LAMP1 or p62 stainings were taken with the same settings. Pictures were transferred to ImageJ, converted into black and white and dots were defined by setting the same threshold for each staining.
The amount of dot number and area was measured in each case in 3-3 sections per brain in at least 3-3 animals per staining. Values were measured in each case in the same area defined in ImageJ and then normalized to the control conditions giving a relative dot number/ area or dot size/ area. The percentage of p62 or AGO2 cell numbers were counted manually based on DAPI staining in ImageJ. All pictures with confocal microscopy were done using a magnification of 63x. Pictures of AGO2 or p62 staining were taken with the same settings. Pictures were transferred to ImageJ, converted into black and white and AGO2 or p62 positive cell counts were defined by setting the same threshold for each staining. Values were measured in each case in the same area defined in ImageJ and then normalized to the cell number for each picture.
